Journal
MEMORIAS DO INSTITUTO OSWALDO CRUZ
Volume 106, Issue -, Pages 64-69Publisher
FUNDACO OSWALDO CRUZ
DOI: 10.1590/S0074-02762011000900008
Keywords
Plasmodium falciparum; pregnancy malaria; placenta; chondroitin sulphate A; vaccine
Categories
Funding
- Bill & Melinda Gates Foundation [47029]
- Grand Challenges in Global Health/Foundation for NIH, DIR, NIAID, NIH
Ask authors/readers for more resources
Malaria during pregnancy can be severe in non-immune women, but in areas of stable transmission, where women are semi-immune and often asymptomatic during infection, malaria is an insidious cause of disease and death for mothers and their offspring. Sequelae, such as severe anaemia and hypertension in the mother and low birth weight and infant mortality in the offspring, are often not recognised as consequences of infection. Pregnancy malaria, caused by Plasmodium falciparum, is mediated by infected erythrocytes (IEs) that bind to chondroitin sulphate A and are sequestered in the placenta. These parasites have a unique adhesion phenotype and distinct antigenicity, which indicates that novel targets may be required for development of an effective vaccine. Women become resistant to malaria as they acquire antibodies against placental IE, which leads to higher haemoglobin levels and heavier babies. Proteins exported from the placental parasites have been identified, including both variant and conserved antigens, and some of these are in preclinical development for vaccines. A vaccine that prevents P. falciparum malaria in pregnant mothers is feasible and would potentially save hundreds of thousands of lives each year.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available